Inventors:
Ronald J. Shebuski - Alexandria VA, US
Samuel B. Ho - San Diego CA, US
Laurie Shekels - Orono MN, US
Robert L. Heinrikson - Plainwell MI, US
Assignee:
MuciMed, Inc. - Kalamazoo MI
International Classification:
A61K 38/17, C12N 9/12, C12N 9/08, C12N 9/04, C12N 9/16, C12N 15/12, C12N 15/63, C12N 5/10, C12N 1/19, C12N 1/00, C12N 1/21, A61K 31/7088, C07H 21/00, A61P 1/00, A61P 29/00, C07K 19/00
US Classification:
514 209, 530395, 435194, 435192, 435190, 435196, 536 234, 4353201, 435348, 435419, 435325, 4352542, 435358, 435366, 435363, 435354, 43525421, 435243, 43525233, 514 44 R
Abstract:
The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease.